Literature DB >> 21850548

Relationship between serum RANKL and RANKL in bone.

D M Findlay1, G J Atkins.   

Abstract

It is now well accepted that the molecule receptor activator of NFκB ligand (RANKL) and osteoprotegerin play key roles in regulating physiological and pathological bone turnover. There are a large number of published reports of circulating RANKL levels in both health and pathology. However, interpretation of these data has been elusive, and the relationship between circulating RANKL and RANKL levels in bone is still not clear. This review explores this subject, documenting the possible origins of circulating RANKL and suggesting additional information that is required before serum RANKL levels can provide useful diagnostic or research information.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21850548     DOI： 10.1007/s00198-011-1740-9

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


  58 in total

1.  Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker?

Authors:  P Spelling; E Bonfá; V F Caparbo; R M R Pereira
Journal:  Scand J Rheumatol       Date:  2008 Nov-Dec       Impact factor: 3.641

2.  The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction.

Authors:  P P Geusens; R B M Landewé; P Garnero; D Chen; C R Dunstan; W F Lems; P Stinissen; D M F M van der Heijde; S van der Linden; M Boers
Journal:  Arthritis Rheum       Date:  2006-06

3.  Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis.

Authors:  Lilian H D van Tuyl; Alexandre E Voskuyl; Maarten Boers; Piet Geusens; Robert B M Landewé; Ben A C Dijkmans; Willem F Lems
Journal:  Ann Rheum Dis       Date:  2010-06-04       Impact factor: 19.103

4.  Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.

Authors:  Bo Abrahamsen; Jacob Vb Hjelmborg; Paul Kostenuik; Lis S Stilgren; Kirsten Kyvik; Stephen Adamu; Kim Brixen; Bente L Langdahl
Journal:  Bone       Date:  2005-04       Impact factor: 4.398

5.  Vitamin D depletion induces RANKL-mediated osteoclastogenesis and bone loss in a rodent model.

Authors:  Paul H Anderson; Rebecca K Sawyer; Alison J Moore; Brian K May; Peter D O'Loughlin; Howard A Morris
Journal:  J Bone Miner Res       Date:  2008-11       Impact factor: 6.741

6.  Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation.

Authors:  K E Naylor; A Rogers; R B Fraser; V Hall; R Eastell; A Blumsohn
Journal:  J Clin Endocrinol Metab       Date:  2003-11       Impact factor: 5.958

7.  The induction of a catabolic phenotype in human primary osteoblasts and osteocytes by polyethylene particles.

Authors:  Gerald J Atkins; Katie J Welldon; Christopher A Holding; David R Haynes; Donald W Howie; David M Findlay
Journal:  Biomaterials       Date:  2009-04-05       Impact factor: 12.479

8.  Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.

Authors:  Thomas J Wilson; Kalyan C Nannuru; Mitsuru Futakuchi; Anguraj Sadanandam; Rakesh K Singh
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

Review 9.  Insights in the application of research-grade diagnostic kits for biomarker assessments in support of clinical drug development: bioanalysis of circulating concentrations of soluble receptor activator of nuclear factor kappaB ligand.

Authors:  Ronald R Bowsher; Jeffrey M Sailstad
Journal:  J Pharm Biomed Anal       Date:  2008-09-27       Impact factor: 3.935

10.  Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.

Authors:  L Alvarez; P Peris; N Guañabens; S Vidal; I Ros; F Pons; X Filella; A Monegal; J Muñoz-Gomez; A M Ballesta
Journal:  Arthritis Rheum       Date:  2003-03
View more
  22 in total

Review 1.  Osteocyte regulation of bone mineral: a little give and take.

Authors:  G J Atkins; D M Findlay
Journal:  Osteoporos Int       Date:  2012-08       Impact factor: 4.507

Review 2.  Relaxin and insulin-like peptide 3 in the musculoskeletal system: from bench to bedside.

Authors:  Alberto Ferlin; Luca De Toni; Marco Sandri; Carlo Foresta
Journal:  Br J Pharmacol       Date:  2016-05-05       Impact factor: 8.739

Review 3.  The Utility of Biomarkers in Osteoporosis Management.

Authors:  Patrick Garnero
Journal:  Mol Diagn Ther       Date:  2017-08       Impact factor: 4.074

4.  The role of serum osteoprotegerin and receptor-activator of nuclear factor-κB ligand in metabolic bone disease of women after obesity surgery.

Authors:  José A Balsa; Christian Lafuente; Jesús M Gómez-Martín; Julio Galindo; Roberto Peromingo; Francisca García-Moreno; Gloria Rodriguez-Velasco; Javier Martínez-Botas; Diego Gómez-Coronado; Héctor F Escobar-Morreale; José I Botella-Carretero
Journal:  J Bone Miner Metab       Date:  2015-10-05       Impact factor: 2.626

5.  Prolonged high force high repetition pulling induces osteocyte apoptosis and trabecular bone loss in distal radius, while low force high repetition pulling induces bone anabolism.

Authors:  Mary F Barbe; Vicky S Massicotte; Soroush Assari; M Alexandra Monroy; Nagat Frara; Michele Y Harris; Mamta Amin; Tamara King; Geneva E Cruz; Steve N Popoff
Journal:  Bone       Date:  2018-02-22       Impact factor: 4.398

6.  Jumping exercise preserves bone mineral density and mechanical properties in osteopenic ovariectomized rats even following established osteopenia.

Authors:  R Okubo; L S Sanada; V A Castania; M J Q Louzada; F J A de Paula; N Maffulli; A C Shimano
Journal:  Osteoporos Int       Date:  2017-01-26       Impact factor: 4.507

7.  Changes of serum soluble receptor activator for nuclear factor-κB ligand after glucocorticoid therapy reflect regulation of its expression by osteoblasts.

Authors:  Kaichi Kaneko; Natsuko Kusunoki; Tomoko Hasunuma; Shinichi Kawai
Journal:  J Clin Endocrinol Metab       Date:  2012-07-12       Impact factor: 5.958

8.  Associations between OPG and RANKL polymorphisms, vertebral fractures, and abdominal aortic calcification in community-dwelling older subjects: the Sao Paulo Ageing & Health Study (SPAH).

Authors:  R M R Pereira; C P Figueiredo; C C Cha; V F Caparbo; R M Oliveira; A S Franco; P R Menezes; I de Castro; L F Onuchic
Journal:  Osteoporos Int       Date:  2016-06-16       Impact factor: 4.507

9.  The relationship between osteoclastogenic and anti-osteoclastogenic pro-inflammatory cytokines differs in human osteoporotic and osteoarthritic bone tissues.

Authors:  Janja Zupan; Radko Komadina; Janja Marc
Journal:  J Biomed Sci       Date:  2012-03-01       Impact factor: 8.410

10.  Circulating Levels of Soluble Receptor Activator of NF- κ B Ligand and Matrix Metalloproteinase 3 (and Their Antagonists) in Asian Indian Patients with Ankylosing Spondylitis.

Authors:  Varun Dhir; Rajni Srivastava; Amita Aggarwal
Journal:  Int J Rheumatol       Date:  2013-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.